J.Jpn. Surg. Soc.. 87(2): 154-161, 1986
Original article
CLINICAL STUDY OF CLONOGENIC ASSAY－WITH REFERENCE TO ADJUVANT CANCER CHEMOTHERAPY AFTER OPERATION
|
Departments of Surgery, Kitasato Institute Hospital, Tokyo, Japan Tetsuro Kubota, Eiji Kawamura, Hiroaki Kurihara*), Kyuya Ishibiki*), Osahiko Abe*) |
The clonogenic assay was performed according to the method of Salmon et al. The dissociated tumor cells were contacted with drugs in a concentration of 1μg/ml for 1hr. (mitomycin C ; MMC) or 2－3wks. (5-fluorouracil ; 5-FU). Fifty percent or more inhibitory rate of the colonies were evaluated as positive. The clinical antitumor effects were assesed by the tumor reduction in non-curatively operated cases and by the survival period after the operation in curatively operated cases.
Overall evaluable cases were 52 of 100 cases with a median cloning efficiency rate of 0.1％. The efficacy rates of the drugs in vitro were found to be 21.3％ for MMC and 31.8％ for 5-FU. The histological differentiations, Stages, pretreatments and cloning efficiency rates were observed to have few influence on the chemosensitivity.
Nineteen non-curatively operated cases were eligible for the comparison between in vitro and in vivo, showing 40％ true positive, 100％ true negative and 84.2％ predictable rates. In curatively operated cases, whereas 2 of 14 cases have died of cancer in not adapted adjuvant cancer chemotherapy group, no cancer deaths were encountered in 7 cases whose adjuvant cancer chemotherapy was evaluated as effective in the clonogenic assay.
From these findings, it was concluded that in vitro clonogenic assay might be useful to select a suitable adjuvant cancer chemotherapy in curatively operated cases as well as cases with advanced carcinomas.
To read the PDF file you will need Adobe Reader installed on your computer.